Predicting Radiotherapy Response in Cervical Cancer
Author Information
Author(s): BS Bolger, RP Symonds, PD Stanton, AB MacLean, R Burnett, P Kelly, TG Cooke
Primary Institution: University Department of Surgery, Glasgow Royal Infirmary
Hypothesis
Can the tumour proliferation rate predict the response to radiotherapy in cervical carcinoma?
Conclusion
Higher tumour proliferation rates are associated with poorer pelvic disease-free survival in cervical cancer patients undergoing radiotherapy.
Supporting Evidence
- Patients with higher BrdUrd labelling had a significantly poorer survival.
- The median follow-up for surviving patients was 34.6 months.
- Elevated BrdUrd labelling was the only significant biological parameter related to locoregional recurrence.
Takeaway
Doctors can measure how fast cancer cells are growing to help decide the best treatment for cervical cancer. If the cells are growing quickly, the treatment might not work as well.
Methodology
The study measured tumour proliferation rates using bromodeoxyuridine labelling and flow cytometry in cervical cancer patients scheduled for radiotherapy.
Limitations
The study did not assess the feasibility of altering radiotherapy schedules based on the findings.
Participant Demographics
Median age of participants was 61 years, with an interquartile range of 47 to 70 years.
Statistical Information
P-Value
0.006
Confidence Interval
1.03-1.21
Statistical Significance
p=0.006
Want to read the original?
Access the complete publication on the publisher's website